

Unknown

From: Macfadden, Wayne  
Sent: Thursday, December 22, 2005 3:04 PM  
To: REDACTED  
Subject: RE: AstraZeneca project



she's too late! (& besides, I'm not that easy!)

-----Original Message-----

From: REDACTED  
Sent: Thursday, December 22, 2005 3:00 PM  
To: Macfadden, Wayne  
Subject: RE: AstraZeneca project

Maybe she wants to REDACTED

-----Original Message-----

From: Macfadden, Wayne [mailto:Wayne.Macfadden@astrazeneca.com]  
Sent: Thursday, December 22, 2005 2:57 PM  
To: REDACTED  
Subject: FW: AstraZeneca project

the bitch finally got back to me!

-----Original Message-----

From: REDACTED  
Sent: Thursday, December 22, 2005 2:10 PM  
To: Macfadden, Wayne  
Subject: Re: AstraZeneca project

Hi, I would love to talk to you about this project but will be away until Jan 3. Can we talk then? M

> Hello REDACTED

>  
> Wanted to follow up my phone message to you with an e-mail.....

> I don't think we've met, but we were referred to you by Dr REDA. I am  
> the

US  
> Medical Director for Seroquel with AstraZeneca, and also the project  
> physician for our two recent successful clinical trials in bipolar  
> depression. One of the exciting aspects of these studies was the  
> reduction of suicidality that most patients experienced, as reflected  
> in depression sub-item scores. Moreover, there was no evidence of rx-  
> emergent suicidality, by looking at AE incidences, or the Columbia  
analysis.

>  
> We would like to expand these findings into a manuscript about  
> Seroquel's apparent effect in reducing suicidality, and are inviting  
> you to take a leadership role in this publication.

>  
> I'll enclose the main manuscript from the 1st study (the 2nd one is  
> unpublished thus far) which may answer some of your questions, but  
> feel

free  
> to call me with any others. Pls let us know of your interest &  
> availability for such an endeavor.

>  
> regards

>  
> Wayne  
>  
> Wayne Macfadaden MD  
> US Medical Director, Seroquel  
> AstraZeneca LTD  
> 302-886-1147  
> wayne.macfadden@astrazeneca.com  
>  
> <<Am J Psychiatry 2005 162 1351-60.pdf>>  
>